Signaling Chains

doi:10.1016/B0-08-045044-X/00083-3

Reference Module in Chemistry, Molecular Sciences and Chemical Engineering

Comprehensive Medicinal Chemistry II

Volume 3, 2007, Pages 189-214

https://doi.org/10.1016/B0-08-045044-X/00083-3 Get rights and content

Whereas a description of the hundreds of existing cell signaling pathways is beyond the scope of this overview, we allow here insight into key cell signaling pathways that are already interesting drug targets or might be considered interesting future targets. Special emphasis was placed on ubiquitine degradation pathways related to stress signaling and inflammation, NFκB and apoptotic pathways, vascular endothelial growth factor receptor-activated cell signaling mechanisms as well as cytokinemediated Signal Transducer and Activator of Transcription signal transduction (STAT).

References (0)

Cited by (0)

Marie-Heélène Teiten received her PhD in Biology in 2003 at the Universiteé Henri Poincareé in Nancy (France). Her research project, performed in the Photodynamic Therapy Unit of the Alexis Vautrin Cancer Center (Nancy, France) under the direction of Prof François Guillemin, focused on the subcellular localization and the phodommages induced by photosensitizers used in photodynamic therapy.

Romain Blasius was born in 1976 in Luxembourg. In 1995 he moved to the Universiteé Libre de Bruxelles (Brussels, Belgium), where he received his BSc degree in chemistry in 1999. He then went on to complete his PhD studies under the supervision of A Kirsch and C Moucheron in the area of photochemistry and photophysics of transition metal complexes with DNA and received his PhD in 2003. He subsequently moved to the Laboratoire de Biologie Moleéculaire et Cellulaire du Cancer in Luxembourg, where he is currently carrying out his research on the resistance of cancer cells toward chemotherapeutic drugs and the inhibition of this resistance via the use of natural compounds.

Franck Morceau (right) received his PhD in molecular pharmacology in 1996 at the University of Reims (France). His research focalizes on molecular mechanisms of erythroid differentiation. He is a staff scientist at the Laboratoire de Biologie Moleéculaire et Cellulaire du Cancer in Luxembourg.

Marc Diederich (left) received his PhD in molecular pharmacology in 1994 at the University of Nancy (France). He is leading the Laboratoire de Biologie Moleéculaire et Cellulaire du Cancer in Luxembourg. Research in this laboratory is mainly focusing on the inhibition of glutathione-based drug resistance mechanism by natural compounds as well as erythroid differentiation mechanisms.

Mario Dicato is Head of Internal Medicine and of the Service of Haematology-Oncology at Luxembourg Medical Centre. Much of his postgraduate training was at the University of Pittsburgh, Pittsburgh, PA, USA and at Harvard University, Boston, MA, USA.

View full text

Comprehensive Medicinal Chemistry II

3.10 - Signaling Chains